Allergy and Immune Disorders, Murdoch Childrens Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia.
Antioxid Redox Signal. 2012 Jul 15;17(2):340-54. doi: 10.1089/ars.2011.4480. Epub 2012 Feb 9.
Histone deacetylase inhibitors (HDACIs) have emerged as a new class of anticancer therapeutics. The hydroxamic acid, suberoylanilide hydroxamic acid (Vorinostat, Zolinza™), and the cyclic peptide, depsipeptide (Romidepsin, Istodax™), were approved by the U.S. Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma in 2006 and 2009, respectively. At least 15 HDACIs are currently undergoing clinical trials either alone or in combination with other therapeutic modalities for the treatment of numerous hematological and solid malignancies.
The potential utility of HDACIs has been extended to nononcologic applications, including autoimmune disorders, inflammation, diseases of the central nervous system, and malaria.
Given the promise of HDACIs, there is growing interest in the potential of dietary compounds that possess HDAC inhibition activity. This review is focused on the identification of and recent findings with HDACIs from dietary, medicinal plant, and microbial sources. We discuss the mechanisms of action and clinical potential of natural HDACIs.
Apart from identification of further HDACI compounds from dietary sources, further research will be aimed at understanding the effects on gene regulation on lifetime exposure to these compounds. Another important issue that requires clarification.
组蛋白去乙酰化酶抑制剂（HDACIs）已成为一类新的抗癌治疗药物。羟肟酸类化合物（伏立诺他，Zolinza™）和环肽类化合物（罗米地辛，Istodax™）分别于 2006 年和 2009 年被美国食品和药物管理局（FDA）批准用于治疗皮肤 T 细胞淋巴瘤。目前至少有 15 种 HDACIs 正在进行临床试验，无论是单独使用还是与其他治疗方式联合使用，都用于治疗多种血液系统和实体恶性肿瘤。
HDACIs 的潜在用途已扩展到非肿瘤应用，包括自身免疫性疾病、炎症、中枢神经系统疾病和疟疾。
鉴于 HDACIs 的潜力，人们对具有 HDAC 抑制活性的膳食化合物的潜在作用越来越感兴趣。本综述重点介绍了来自膳食、药用植物和微生物来源的 HDACIs 的鉴定和最新发现。我们讨论了天然 HDACIs 的作用机制和临床潜力。
除了从膳食来源中进一步鉴定 HDACI 化合物外，还将进一步研究这些化合物对基因调控的影响，以及终生暴露于这些化合物的影响。另一个需要澄清的重要问题是。
